series-a
Stage
2024
Founded
2
Investors
About
OverT Bio develops off-the-shelf, programmed gamma delta T cell therapies that target solid tumors by combining AI-driven genetic discovery with scalable manufacturing.
Explore OverT Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.